Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis
Key facts
- Who runs it
- Asian Institute of Gastroenterology, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 107 people enrolled
- Started
- 1 Sept 2021
- Ended
- 30 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Non-enteric coated pancreatic enzyme preparation
- Record updated
- 4 September 2024
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Chronic pancreatitis of at least 3 years
- At least 3 episodes of pain in the past 3 months
- Pain score of at least 3 on VAS (0-10)
- Age 18-60yrs
- Both genders
Who cannot take part
- Active substance use (alcohol, smoking, smokeless tobacco, illicit drugs)
- Pancreatic cancer
- Other chronic painful conditions
- Acute pancreatitis episode at the time of enrolment
- Pregnancy and lactation
- Inability to give informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pain in CP entails several independent yet overlapping mechanisms including oxidative stress-mediated parenchymal inflammation, pancreatic and central neuropathy and neuroplasticity. Medical modalities for long-term pain management includes antioxidants and neuromodulators. Pancreatic enzymes are also invariably used for pain management. CP with ductal obstruction and pain is treated with either endotherapy or drainage surgery. However, it has been observed that a substantially increasing proportion of patients experience pain recurrence as the duration of follow-up after endotherapy or surgery gets longer.
Read full original descriptionShow less
Neural and dietary (proteins) stimuli activate CCK receptors in D1 \& D2 which gives a positive feedback signal for pancreatic secretion. Once enzyme secretion starts, due to ductal and interstitial/tissue hypertension, nociception begins that results in pain. Blockade of the duodenal CCK receptors could inhibit the positive feedback loop, thereby reducing pancreatic secretion and resulting pain. Currently available enteric coated enzyme supplements are released throughout the small bowel and therefore may not be released sufficiently in the duodenum to effectively suppress the feedback loops. High doses of proteases (~25k-30k) would be required to block the receptors, while most of the currently available preparations have higher lipase but not proteases.
This led to the investigators' hypothesis that negative feedback of CCK by non enteric coated pancreatic enzymes could ameliorate pain in a more effective manner by NE-PERT.
The 2 groups in the trial
- NE PERTTreatment being tested
Non-enteric coated pancreatic enzyme capsules containing 30,000U of protease will be provided three times a day along with food (breakfast, lunch and dinner)
Treatment: Non-enteric coated pancreatic enzyme preparation
- PlaceboPlacebo, for comparison
Similar appearing glucose capsules will be provided three times a day along with food (breakfast, lunch and dinner)
Treatment: Non-enteric coated pancreatic enzyme preparation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis: a Double -Blinded Placebo Controlled Randomized Trial (NE-PERT Trial)
- Publications
- Record updated
- 4 September 2024